Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2015-02-23 Board/Management Inform…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Professor Elliott steps down from executive position 2 pages 273.2KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 24 February 2015. It announces that Professor Elliott is stepping down from his executive position but will remain a board director. The content focuses on management changes and does not contain financial data, earnings, or detailed reports. It is not a full annual or interim report, nor an earnings release or investor presentation. The document is a formal announcement about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4724 characters, which is consistent with a typical announcement rather than a full report.
2015-02-23 English
Half Yearly Report and Accounts 23 pages 347.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a 'Half yearly report ended 31 December 2014' and contains detailed financial statements, directors' report, auditor's review report, consolidated statement of profit or loss, financial position, cash flows, and notes to the financial statements. It covers a six-month period, which is shorter than a full fiscal year, and includes substantive financial data and analysis. The document is not merely an announcement or a brief summary but a comprehensive interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2015
2015-02-17 English
Appendix 3B 9 pages 52.5KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares by Living Cell Technologies Limited. It includes specifics such as the class of securities, number of securities issued, issue price, purpose of the issue, and quotation details for the Australian Securities Exchange (ASX). The document references ASX rules and compliance, and it is a formal announcement related to the company's capital raising activities. There are no financial statements or management discussion of financial results, so it is not an Annual Report or Interim Report. It is not a regulatory certification or legal proceeding. The content clearly fits the category of a capital or financing update, specifically a new share issue announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2015-02-01 English
Appendix 4C - quarterly 7 pages 97.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2014' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as reconciliation of cash and payments to directors. The document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The Appendix 4C is a standard quarterly cash flow report required by the ASX for entities admitted on the basis of commitments. This fits the definition of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year, including actual financial statements and analysis. It is not an earnings release (ER) because it contains detailed financial statements, nor is it a report publication announcement (RPA) because the report itself is included, not just an announcement of its availability. Therefore, the correct classification is IR. Q2 2015
2015-01-27 English
Change of Registered Office Address 3 pages 22.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 January 2015 regarding a change of the company's registered office address. It contains no financial data, no discussion of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no detailed report content. The document is short (4564 characters) and serves as a formal notification of an administrative change. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-01-18 English
LCT completes patient implants in Parkinson's trial 2 pages 23.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 15 December 2014. It announces the completion of patient implants in a Phase I/IIa clinical trial for Parkinson's disease. The content focuses on clinical trial progress and future presentation plans, with no financial data, regulatory filings, or detailed financial reports included. The document is relatively short (5449 characters) and serves as a progress update rather than a financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement related to clinical trial progress, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2014-12-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.